Anticancer Potential of Artemisinin Derivative-Dihydroartemisinin
DOI:
https://doi.org/10.54097/hset.v33i.5327Keywords:
Dihydroartemisinin, Artemisinin Derivative, Anticancer, Drug DesignAbstract
Artemisinin is famous for its effectiveness of treating malaria for years. Potential of artemisinin in treating cancer has been recently recognized. In this study, the anticancer potential of artemisinin and its derivative dihydroartemisinin (DHA) is comprehensively illustrated, including brief introduction of background and clinical applications. Artemisinin derivatives, especially dihydroartemisinin, of which the anticancer mechanism such as induction of apoptosis, inhibition of peripheral blood vessels has also been depicted. Cases of clinical study of cervical cancer and breast cancer are also reported to further proof the anticancer efficiency of dihydroartemisinin. Finally, summary of perspectives and significance of artemisinin and DHA is also provided.
Downloads
References
Freddie Bray, Jacques Ferlay. GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries [R]. Global cancer statistics, 2018
Xinchi Feng, Shijie Cao. Traditional application and modern pharmacological research of Artemisia annua L [J]. Pharmacology & Therapeutics, 2020, 16:107650
Anna L Greenshields, Trevor G Shepherd. Contribution of reactive oxygen species to ovarian cancer cell growth arrest and killing by the anti-malarial drug artesunate [J]. Mol. Carcinog. 2016, 56: 75-93
Dai X, Zhang X, Chen W, Chen Y, Zhang Q, Mo S, Lu J. Dihydroartemisinin: A Potential Natural Anticancer Drug [J]. Int J Biol Sci. 2021, 16; 17(2):603-622.
BD Editors. Apoptosis. [B] 2017
Wang D, Zhong B, Li Y, Liu X. Dihydroartemisinin increases apoptosis of colon cancer cells through targeting Janus kinase 2/signal transducer and activator of transcription 3 signaling [J]. Oncol Lett. 2018,15(2):1949-1954
Zhang S, Shi L, Ma H, Li H, Li Y, Lu Y, Wang Q, Li W. Dihydroartemisinin induces apoptosis in human gastric cancer cell line BGC-823 through activation of JNK1/2 and p38 MAPK signaling pathways [J]. J Recept Signal Transduct Res. 2017,37(2):174-180
Ma Z, Woon CY, Liu CG, Cheng JT, You M, Sethi G, Wong AL, Ho PC, Zhang D, Ong P, Wang L, Goh BC. Repurposing Artemisinin and its Derivatives as Anticancer Drugs: A Chance or Challenge? [J] Front Pharmacol. 2021,31;12:828856
Lucibello M, Adanti S, Antelmi E, Dezi D, Ciafrè S, Carcangiu ML, Zonfrillo M, Nicotera G, Sica L, De Braud F, Pierimarchi P. Phospho-TCTP as a therapeutic target of Dihydroartemisinin for aggressive breast cancer cells. [J] Oncotarget. 2015 ,10;6(7):5275-91
Wenhe Zhu, Yawei Li, et.al, Dihydroartemisinin suppresses glycolysis of LNCaP cells by inhibiting PI3K/AKT pathway and downregulating HIF-1α expression. [J] Life Science, 2019,15(233):116730
Tsui KH, Wu MY, Lin LT, Wen ZH, Li YH, Chu PY, Li CJ. Disruption of mitochondrial homeostasis with artemisinin unravels anti-angiogenesis effects via auto-paracrine mechanisms. [J] Theranostics. 2019,17;9(22):6631-6645
Chen J, Guo Z, Wang HB, Zhou JJ, Zhang WJ, Chen QW. Multifunctional mesoporous nanoparticles as pH-responsive Fe (2+) reservoirs and artemisinin vehicles for synergistic inhibition of tumor growth. [J] Biomaterials. 2014 ;35(24):6498-507
Lu ZH, Peng JH, Zhang RX, Wang F, Sun HP, Fang YJ, Wan DS, Pan ZZ. Dihydroartemisinin inhibits colon cancer cell viability by inducing apoptosis through up-regulation of PPARγ expression. [J] Saudi J Biol Sci. 2018;25(2):372-376
Jansen FH, Adoubi I, J C KC, DE Cnodder T, Jansen N, Tschulakow A, Efferth T. First study of oral Artenimol-R in advanced cervical cancer: clinical benefit, tolerability and tumor markers. [J] Anticancer Res. 2011; 31(12):4417-22.
Downloads
Published
Issue
Section
License
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
How to Cite
